Tumor-targeted nanodelivery systems to improve early mri...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 39/395 (2006.01)

Patent

CA 2638899

A method of making antibody- or antibody fragment-targeted immunoliposomes for the systemic delivery of molecules to treat and image diseases, including cancerous tumors, providing immunoliposomes and compositions, as well as methods of imaging various tissues. The liposome complexes are useful for encapsulation of imaging agents, for example, for use in magnetic resonance imaging. The specificity of the delivery system is derived from the targeting antibodies or antibody fragments.

Cette invention concerne une méthode pour fabriquer des immunoliposomes visant des fragments d'anticorps ou des anticorps pour administration systémique de molécules dans le but de traiter et de produire une image de maladies, y compris des tumeurs cancéreuses. L'invention concerne aussi des immunoliposomes et des compositions, ainsi que des méthodes d'imagerie de divers tissus. Les complexes de liposomes sont utiles pour l'encapsulation d'agents d'imagerie, par exemple, à utiliser en imagerie par résonance magnétique. La spécificité du dispositif d'administration découle du ciblage des anticorps ou des fragments d'anticorps.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Tumor-targeted nanodelivery systems to improve early mri... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tumor-targeted nanodelivery systems to improve early mri..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor-targeted nanodelivery systems to improve early mri... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1812674

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.